Shares of Novo Nordisk A/S (NYSE: NVO) dropped 1.9%today, closing at $48.25, just a whisker above the 52-week low of $45.05. Sometimes we see a divergence in share price and sentiment, but with Novo Nordisk they’re actually well correlated.
Discussion on Reddit has remained uniformly bearish throughout November. Novo Nordisk is trading more than 50% below its 52-week high, a stunning collapse for a company that was once viewed as the premier play on the obesity treatment revolution.
While not the only reason, it’s easy to see a notable downward trend in Google Trends for both of Novo Nordisk’s premier GLP-1 products, Ozempic and Wegovy
Despite strong underlying fundamentals like a 71.5% return on equity and huge 32.9% net income margin, retail traders are persistently skeptical about the Danish drugmaker’s future.
Activity on r/WallStreetBets has been consistently negative. Sentiment scores have ranged from a low of 18, to only as high as 30 this moth. When 50/100 considered perfectly neutral, this is deep in bearish territory. The most active period occurred on November 10, when one poster asked “where’s the n bottom?”
Novo Nordisk down another 2% today, where’s the bottom?
by
u/BearishOnPharma in
wallstreetbets
The Case Against Novo Nordisk
Retail investors are focusing on fundamental deterioration with Novo Nordisk’s position as a leader in GLP-1 treatments. The concerns are rooted in:
-
Earnings collapsed 26.5% year-over-year despite operating in the supposedly booming obesity treatment market
-
Revenue growth slowed to just 5.1% YoY, a steep deceleration
-
Competitive pressure from Eli Lilly (NYSE: LLY) has intensified, with Lilly’s Zepbound gaining market share rapidly
All of this means the stock now trades at a forward P/E of just 11.99, a far cry from the premium valuations of 1-2 years ago.
Wall Street analysts appear equally uncertain, with two out of eleven analysts rating the stock a sell, unusual for a major pharmaceutical name. The consensus price target of $56.91 represents only 15.8% upside from current levels, hardly inspiring confidence. The company’s official description as “a premier global healthcare company at the forefront of innovation” rings hollow when earnings are contracting at double-digit rates.
Trading Near Multi-Year Lows
Novo Nordisk now sits precariously close to retesting its 52-week low, with minimal technical, institutional, or retail support visible. Competitive dynamics in the GLP-1 space remain a key factor, particularly market share trends between Wegovy and Eli Lilly’s Zepbound. The r/WallStreetBets community continues to provide real-time sentiment that has proven prescient during this decline.
The New Report Shaking Up Retirement Plans
You may think retirement is about picking the best stocks or ETFs, but you’d be wrong. See even great investments can be a liability in retirement. The difference comes down to a simple: accumulation vs distribution. The difference is causing millions to rethink their plans.
The good news? After answering three quick questions many Americans are finding they can retire earlier than expected. If you’re thinking about retiring or know someone who is, take 5 minutes to learn more here.